Medco Health Solutions
on Thursday completed its acquisition of
United BioSource Corporation
in an all-cash transaction valued at approximately $730 million, creating a complementary and comprehensive research organization that extends Medco's core capabilities in data analytics and research to accelerate pharmaceutical knowledge.
UBC is now a wholly-owned subsidiary of Medco that will run independently from Medco's core business to ensure compliance with contractual requirements and client expectations. Dr. Robert S. Epstein, Medco's chief medical officer and president of the Medco Research Institute™, will have overall responsibility for the UBC business. UBC Chief Executive Officer Ethan Leder will continue in his position, overseeing the company's current operations.
The transaction was funded with the proceeds of Medco's recently completed senior notes offering. The new business is expected to be slightly accretive to Medco shareholders in 2011, excluding one-time items and amortization.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.